seaporttx.comHealthcare / BioTech & PharmaFounded: 2024
Seaport Therapeutics is a clinical-stage biopharmaceutical company working to develop neuropsychiatric medicines in areas of unmet patient needs. Candidates are treated with medicines based on the Glyph platform, which is designed with a mission to enable oral bioavailability, as well as bypass first-pass metabolism, and reduce hepatotoxicity, among other side effects. Seaport Therapeutics was founded by Steven Paul MD, Bharatt Chowrira Ph.D, and Eric Elenko Ph.D in 2024 and is headquartered in Boston, MA.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Seaport Therapeutics.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.